Key result
The NOAAH trial is designed to compare amlodipine/valsartan versus bisoprolol/hydrochlorothiazide to demonstrate a 5-mmHg difference in sitting systolic pressure in native African patients.
Why the study?
Does amlodipine/valsartan reduce sitting systolic blood pressure compared to bisoprolol/hydrochlorothiazide in native African patients with uncomplicated hypertension?
Population
Native African patients aged 30-69 years with uncomplicated hypertension and two or fewer associated risk…
Comparison
Amlodipine/valsartan 5/160 mg once daily vs Bisoprolol/hydrochlorothiazide 5/6.25 mg once…
Design
RCT, Randomized to once daily bisoprolol/hydrochlorothiazide or…
Follow-up
6 months
Authors
Loading...
Addresses evidence gap for hypertension combos in Africans; extends RCT data to this underrepresented population.
RCT (n=180)
randomized
Yes
Does amlodipine/valsartan reduce sitting systolic blood pressure compared to bisoprolol/hydrochlorothiazide in native African patients with uncomplicated hypertension?
The NOAAH trial is designed to compare the efficacy of a newer non-diuretic-based combination (amlodipine/valsartan) versus an older diuretic-based combination (bisoprolol/hydrochlorothiazide) for hypertension in native sub-Saharan Africans.
Odili et al. (2011) conducted an RCT in uncomplicated hypertension (n=180). amlodipine/valsartan vs. bisoprolol/hydrochlorothiazide 5/6.25 mg once daily was evaluated on sitting systolic pressure. The NOAAH trial is designed to compare amlodipine/valsartan versus bisoprolol/hydrochlorothiazide to demonstrate a 5-mmHg difference in sitting systolic pressure in native African patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: